You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
昊海生物科技(06826.HK):2021年歸母淨利同比增長53.19%
格隆匯 02-27 23:53

格隆匯2月27日丨昊海生物科技(06826.HK)發佈業績快報,2021年度,集團實現營業收入約人民幣17.66億元,同比增長約32.57%;實現利潤總額約人民幣3.82億元,同比增長約48.81%;實現歸屬於母公司擁有人的淨利潤約人民幣3.52億元,同比增長約53.19%;實現歸屬於母公司擁有人的扣除非經常性損益的淨利潤約人民幣3.27億元,同比增長約58.38%。

於報吿期內,隨着國內新冠肺炎疫情得到有效控制,疫情對於集團經營活動的影響逐漸減弱,集團各產品線收入均實現大幅增長。於報吿期內,集團毛利率與2020年相比穩中微降,主要原因系人工晶狀體產品部份型號在帶量採購區域銷售價格下降所致,另外,公司收購的歐華美科(天津)醫學科技有限公司自2021年9月開始,被納入公司合併範圍,其射頻及激光醫療美容設備和家用美容儀器等業務毛利率與集團原有業務相比較低,對集團整體毛利率水平造成一定影響。於報吿期內,集團持續加大研發投入,多個眼科和醫美的在研項目持續進行或進入臨牀試驗階段,研發支出較2020年增長較多。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account